Download MendeleyDiscovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10s-loop down conformation.
Stauffer, S.R., Stanton, M.G., Gregro, A.R., Steinbeiser, M.A., Shaffer, J.R., Nantermet, P.G., Barrow, J.C., Rittle, K.E., Collusi, D., Espeseth, A.S., Lai, M.T., Pietrak, B.L., Holloway, M.K., McGaughey, G.B., Munshi, S.K., Hochman, J.H., Simon, A.J., Selnick, H.G., Graham, S.L., Vacca, J.P.(2007) Bioorg Med Chem Lett 17: 1788-1792
- PubMed: 17257835
- DOI: https://doi.org/10.1016/j.bmcl.2006.12.051
- Primary Citation of Related Structures:
2OAH - PubMed Abstract:
A series of low-molecular weight 2,6-diamino-isonicotinamide BACE-1 inhibitors containing an amine transition-state isostere were synthesized and shown to be highly potent in both enzymatic and cell-based assays. These inhibitors contain a trans-S,S-methyl cyclopropane P(3) which bind BACE-1 in a 10s-loop down conformation giving rise to highly potent compounds with favorable molecular weight and moderate to high susceptibility to P-glycoprotein (P-gp) efflux.
Organizational Affiliation:
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. shaun_stauffer@merck.com
